Sunday, December 22nd, 2024

Nanofilm Technologies Int’l Ltd Reports Strong Revenue Growth and Positive Outlook for FY24

Company Overview

Nanofilm Technologies Int’l Ltd is a deep technology company specializing in advanced materials and filtered cathodic vacuum arc (FCVA) coating technologies. The company is recognized for its commitment to ESG and sustainable production methods.

Financial Performance

  • 3Q24 Revenue: Increased by 10% year-on-year (yoy) to S$60 million, with a quarter-on-quarter growth of 38%.
  • Advanced Materials Business Unit (AMBU): Contributed to revenue growth with an 11% yoy increase, driven mainly by a 27% yoy growth in the smartphones and tablets sub-segments.
  • Nanofabrication Business Unit (NFBU): Revenue rose 8% yoy to S$8 million, benefiting from higher allocations for smart wearable products.
  • Industrial Equipment Business Unit (IEBU): Experienced flat yoy revenue at S$3 million due to sluggish demand.
  • Sydrogen Energy: Notably, revenue surged by 688% yoy (low base effect) in 3Q24 as coating production for hydrogen fuel cell bipolar plates used in automobiles increased.

Guidance and Outlook

  • FY24 Guidance: Management expects FY24 revenue and net profit to exceed FY23 levels, barring unforeseen circumstances. The company anticipates lower capital expenditures (capex) in FY24.
  • Production Expansion: The Vietnam Plant 2 has commenced small-scale production for customers, while the India plant is expected to start production for its key customer by the end of 4Q24 or 1Q25.

Analyst Recommendation

  • Rating: The broker maintains a Reduce call for the stock, citing that the current share price has factored in the expected recovery in FY25-26 net profit.
  • Target Price: The target price has been raised to S$0.69 from the previous S$0.59, based on an updated price-to-earnings (P/E) multiple.

Risk Factors

  • Upside Risks: New order wins from customers, faster operational progress at joint ventures (JVs) like ApexTech and Sydrogen Energy could enhance net profit contributions. A strong demand upturn is also a positive factor.
  • De-rating Catalysts: High customer concentration and rising operational costs as the company expands into new regions and sectors.

Market Data

  • Current Price: S$0.825
  • Market Cap: Approximately US$406.7 million
  • Average Daily Turnover: US$1.87 million

Shareholder Information

  • Major Shareholders:
    • Pearl Yard Holdings: 38.6%
    • Venezio Investments: 7.3%

Analyst Details

  • Analyst: William TNG, CFA

Document Details

  • Date: October 29, 2024
  • Broker: CGS International Securities

Genting Malaysia Faces $600 Million Lawsuit Amid Recovery Efforts and Casino Expansion Plans

Date of Report: October 15, 2024Broker: CGS International Securities Complaint and Legal Risks On October 14, 2024, Genting Malaysia (GENM) announced that its indirect subsidiary, Genting Americas Inc. (GAI), was named in a complaint...

Encouraging Sales During Golden Week Fuel Optimism as Policy Implementation Strengthens Fundamentals in 4Q24

Golden Week Sales Surge: Policy Implementation and Market Fundamentals Set for 4Q24 Revival UOB Kay HianOctober 10, 2024 The Chinese property market is witnessing a turnaround, with significant developments during Golden Week 2024 and...

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals 🏢 Sino Biopharmaceutical (1177 HK) – Leading the Charge with Innovative Drug Development Recommendation: BUY Target Price: Not specified Stop Loss: Not...